Kyn Therapeutics Banks $49M to Advance Cancer Immunometabolism Therapies Post author:Sam Post published:December 13, 2017 Post category:BioPharma Investors were Atlas Venture and OrbiMed. Source: BioSpace You Might Also Like Growing Catalent Takes Out Cook Pharmica in $950 Million Deal September 18, 2017 AstraZeneca PLC CEO Breaks Silence on Teva Rumors, Urges Staff to Remain Focused in Leaked Memo July 20, 2017 iTeos Therapeutics Appoints As Vice President, Corporate Development June 28, 2017
AstraZeneca PLC CEO Breaks Silence on Teva Rumors, Urges Staff to Remain Focused in Leaked Memo July 20, 2017
